RGEN Repligen Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN

Price (delayed)

$140.79

Market cap

$7.87B

P/E Ratio

502.82

Dividend/share

N/A

EPS

$0.28

Enterprise value

$7.82B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
RGEN's quick ratio has surged by 172% year-on-year but it is down by 9% since the previous quarter
The company's net income has shrunk by 91% YoY and by 64% QoQ
RGEN's EPS has dropped by 91% year-on-year and by 63% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.repligen.com/
Peers: NVAX BMRN NBIX GE

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
55.88M
Market cap
$7.87B
Enterprise value
$7.82B
Valuations
Price to earnings (P/E)
502.82
Price to book (P/B)
3.98
Price to sales (P/S)
12.93
EV/EBIT
213.03
EV/EBITDA
73.57
EV/Sales
12.88
Earnings
Revenue
$607.45M
EBIT
$36.73M
EBITDA
$106.35M
Free cash flow
$109.54M
Per share
EPS
$0.28
Free cash flow per share
$1.96
Book value per share
$35.33
Revenue per share
$10.89
TBVPS
$26.44
Balance sheet
Total assets
$2.85B
Total liabilities
$878.67M
Debt
$737.73M
Equity
$1.97B
Working capital
$954.7M
Liquidity
Debt to equity
0.37
Current ratio
6.35
Quick ratio
5.03
Net debt/EBITDA
-0.4
Margins
EBITDA margin
17.5%
Gross margin
42.6%
Net margin
2.4%
Operating margin
4.2%
Efficiency
Return on assets
0.6%
Return on equity
0.8%
Return on invested capital
3.7%
Return on capital employed
1.4%
Return on sales
6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
6.37%
1 week
13.71%
1 month
10.86%
1 year
-20.01%
YTD
-21.7%
QTD
11.68%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$607.45M
Gross profit
$258.98M
Operating income
$25.35M
Net income
$14.84M
Gross margin
42.6%
Net margin
2.4%
The company's net income has shrunk by 91% YoY and by 64% QoQ
The net margin has plunged by 89% YoY and by 63% from the previous quarter
The operating income has plunged by 87% YoY and by 54% from the previous quarter
The operating margin has plunged by 83% YoY and by 51% from the previous quarter

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
RGEN P/E details
P/E
502.82
P/B
3.98
P/S
12.93
EV/EBIT
213.03
EV/EBITDA
73.57
EV/Sales
12.88
RGEN's EPS has dropped by 91% year-on-year and by 63% since the previous quarter
The stock's P/E is 84% above its last 4 quarters average of 257.5
The P/B is 34% less than the 5-year quarterly average of 5.7 and 20% less than the last 4 quarters average of 4.7
RGEN's P/S is 31% below its 5-year quarterly average of 17.7 and 14% below its last 4 quarters average of 14.2
The revenue has contracted by 22% YoY and by 4.9% from the previous quarter

Efficiency

How efficient is Repligen business performance
The return on equity has dropped by 91% year-on-year and by 62% since the previous quarter
RGEN's ROA has dropped by 91% year-on-year and by 63% since the previous quarter
The ROIC has plunged by 86% YoY and by 50% from the previous quarter
RGEN's return on sales has dropped by 76% year-on-year and by 42% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
RGEN's quick ratio has surged by 172% year-on-year but it is down by 9% since the previous quarter
Repligen's current ratio has surged by 153% YoY but it has decreased by 10% QoQ
The debt is 63% less than the equity
The debt has soared by 75% YoY and by 3.6% from the previous quarter
Repligen's debt to equity has soared by 68% YoY and by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.